Dashboard
Financial statements
MRNA

Company financials

Moderna

Health Care Biotechnology Cambridge, Massachusetts Last filing Feb 20, 2026 · FY2025
Revenue FY2025
$1.9B
3y CAGR -53.4% P2
Net income FY2025
$-2.8B
Net margin -145.2% P2
Total assets FY2025
$12.3B
ROA -22.9% P2
Operating cash flow FY2025
$-1.9B
FCF margin -106.2% P2
10 yrs · FY2016–FY2025 9 filed · 0 derived · 0 blank

Year-over-year change per cell; first column has no prior.

Balance Sheet

Assets, liabilities, and equity

33 accounts · 10 years
Total assets $12.3B
Total liabilities $3.7B
Shareholders equity $8.7B
Account 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 Trend
Assets
Cash and Cash Equivalents +34.7% -33.7% -9.3% -53.2% +161.0% +1012.4% -64.2% +346.0%
Short Term Investments -37.2% -10.5% -14.9% +72.6% +95.5% +128.8% +0.5%
Accounts Receivable -48.6% -59.9% -35.6% -56.4% +128.3% +27534.3% -56.9%
Inventory +30.8% -42.1% -78.7% -34.1% +2997.1%
Prepaid Expenses -31.9% -4.5% -47.5% +64.1% +188.7% +1199.6% -31.7%
Other Current Assets -22.4% -34.1% +35.4% +18.2%
Total Current Assets -19.2% -21.6% -23.1% -16.4% +155.2% +457.9% -27.8%
Property,Plant and Equipment -2.8% +12.9% -3.6% +62.6% +318.0% -100.0%
Operating Lease Assets -5.3% +6.5% +489.3% -14.8% +57.4% +4.4%
Goodwill +0.0% +0.0%
Intangible Assets +12.5% -9.1%
Deferred Tax Assets +0.0% +0.0% -91.8% +201.2% +543.3% +38.8% +139.8%
Other Noncurrent Assets +1.9% -13.3% -30.7% +2805.9% +1708.5% -2.6% -27.0%
Total Assets -12.8% -23.2% -28.7% +4.8% +236.2% +361.6% -19.0%
Liabilities
Accounts Payable -21.7% -22.1% +6.8% +61.3% +1545.0% +158.9% -77.3%
Accrued Liabilities -2.9% -20.6% -14.4% +42.7% +213.5% +594.1% -14.4%
Deferred Revenue -35.3% -73.1% -72.1% -67.4% +61.7% +6008.3%
Operating Lease Liabilities +21.4% -44.0% -28.6% -23.9% +670.3% +66.6%
Other Current Liabilities -16.3% +234.8% -73.5% +10.7% +568.3% +564.9% +46.2%
Total Current Liabilities -9.9% -26.8% -38.8% -46.1% +108.0% +2966.6% -35.8%
Deferred Revenue Noncurrent +163.8% -30.1% -87.7% +9.4% +246.6% +27.6% +1289.1%
Operating Lease Liabilities Noncurrent -2.7% +4.4% +598.9% -13.2% +8.8% +4.0%
Deferred Tax Liabilities +7.8% -40.5% +69.4% +14.5% +294.7% +38.8% +139.8%
Other Noncurrent Liabilities +6.7% +4.3% +89.6% +77.6% +4001.5% +1242.8% -46.5% -72.6%
Total Liabilities +13.8% -29.1% -32.1% -36.0% +120.4% +1051.8% -4.0%
Equity
Preferred Stock
Common Stock -100.0% +17.6% +3.0%
Additional Paid In Capital +59.6% +133.4% -68.4% -72.1% -12.3% +79.9% +5.2%
Retained Earnings -28.1% -26.2% -25.7% +84.0% +543.9% -49.9% -48.7%
Treasury Stock -100.0% -65.2% +666.7%
Accumulated Other Comprehensive Income +550.0% +91.9% +66.8% -1441.7% -898.9% +66.5% +236.7%
Total Stockholders Equity -20.6% -21.3% -27.6% +35.2% +452.3% +118.0% -23.2% +377.5% -64.7%
Total Liabilitiesand Equity -12.8% -23.2% -28.7% +4.8% +236.2% +361.6% -19.0%

Key Ratios

Margins, returns, liquidity, leverage, efficiency

Computed at import · 10 years
Ratio 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016
Profitability
Gross margin +55.3% +54.8% +31.5% +71.9% +85.8% +99.0% +100.0% +100.0%
Operating margin -158.1% -121.9% -61.9% +48.9% +72.0% -95.0% -906.8% -306.0% -130.9% -206.4%
Net margin -145.2% -110.0% -68.8% +43.4% +66.1% -93.0% -853.7% -284.8% -124.3% -199.5%
FCF margin -106.2% -125.3% -55.9% +23.8% +72.2% +244.0% -815.5% -323.3% -189.4% +31.0%
Growth
Revenue CAGR (3y) -53.4% -44.0% +104.3% +583.9% +415.2% +57.4% -17.8%
Returns
ROE -32.6% -32.7% -34.0% +43.7% +86.3% -29.2% -43.7% -25.1% +46.4% +64.6%
ROA -22.9% -25.2% -25.6% +32.3% +49.5% -10.2% -32.3% -19.6%
ROIC -42.5%
Liquidity
Current ratio 3.29x 3.67x 3.42x 2.73x 1.76x 1.43x 7.89x 7.02x
Quick ratio 1.40x 1.04x 1.26x 0.93x 1.10x 0.91x 1.68x 3.01x
Leverage
D/E 0.43x 0.30x 0.33x 0.35x 0.74x 1.86x 0.35x 0.28x
Interest coverage -1024.67x -164.38x -111.55x 324.83x 782.12x -76.30x -83.27x
Efficiency
Asset turnover 0.16x 0.23x 0.37x 0.74x 0.75x 0.11x 0.04x 0.07x
Cash conversion cycle -34d -31d +23d +57d +222d +1917d

Valuation

Price against fundamentals

FY2025 fundamentals · no price

No price data cached, so there is nothing to multiply. Load prices from the Stock Data tab and this panel reprices itself.

Notes

Your annotations

Not watched
Saving notes adds MRNA to your watchlist.